Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.

PURPOSE Vesicular stomatitis virus has been investigated as an oncolytic agent for cancer therapy because it preferentially replicates in tumor but not in normal cells due to the lack of a robust interferon antiviral system in transformed cells. However, wild-type vesicular stomatitis virus can induce a strong systemic immunological response and replicate in the central nervous system, potentially limiting its clinical usefulness. We report the construction of the recombinant, replication restricted vesicular stomatitis virus encoding SV5-F, which can induce syncytial formation with enhanced oncolytic properties against TRAMP-C2 tumors in an immunocompetent mouse model of prostate cancer. MATERIALS AND METHODS We constructed the SV5-F recombinant restricted virus vector by replacing the vesicular stomatitis virus G gene with that of the SV5-F transgene to generate rVSV-DeltaG-SV5-F. Morphological changes and DNA fragmentation induced by rVSV-DeltaG-GFP or rVSV-DeltaG-SV5-F were determined by phase contrast microscopy and gel electrophoresis. In vitro cytotoxicity by recombinant vesicular stomatitis virus was done by MTT assay. In vivo study of rVSV treatment was done in immunocompetent mice by subcutaneous administration of TRAMP-C2 cells. RESULTS In vitro characterization of the recombinant fusogenic VSV-DeltaG vector on TRAMP-C2 cells showed significantly enhanced apoptotic and cytotoxic effects relative to a similar virus encoding green fluorescent protein, that is rVSV-DeltaG-GFP. Regardless of initial tumor size intratumor rVSV-DeltaG-SV5-F administration in mice bearing subcutaneous TRAMP-C2 tumors resulted in a significantly reduced tumor load over that of the nonfusogenic green fluorescent control virus and of heat inactivated recombinant vesicular stomatitis virus in treated animals (p <0.01). CONCLUSIONS Results show that G complemented recombinant VSV-DeltaG vectors, especially rVSV-DeltaG-SV5-F, are an effective oncolytic agent against mouse prostate cancer cells in vitro and in an in vivo immunocompetent mouse model system.

[1]  Mark A. Miller,et al.  Adjuvanticity of an IL-12 fusion protein expressed by recombinant deltaG-vesicular stomatitis virus. , 2002, Cellular immunology.

[2]  M. Barna,et al.  Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity , 1995, Journal of virology.

[3]  A. García-Sastre,et al.  Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  David A. Chesler,et al.  The role of IFN-γ in immune responses to viral infections of the central nervous system , 2002 .

[5]  D. Lyles,et al.  Vesicular Stomatitis Viruses Expressing Wild-Type or Mutant M Proteins Activate Apoptosis through Distinct Pathways , 2005, Journal of Virology.

[6]  John K. Rose,et al.  Relative Neurotropism of a Recombinant Rhabdovirus Expressing a Green Fluorescent Envelope Glycoprotein , 2002, Journal of Virology.

[7]  A. Sanchez,et al.  A system for functional analysis of Ebola virus glycoprotein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[8]  B. Foster,et al.  Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. , 1997, Cancer research.

[9]  C. López-Iglesias,et al.  Effects of adenovirus‐mediated SV5 fusogenic glycoprotein expression on tumor cells , 2003, The journal of gene medicine.

[10]  Mark A. Miller,et al.  Recombinant replication-restricted VSV as an expression vector for murine cytokines. , 2004, Protein expression and purification.

[11]  R. Lamb,et al.  Expression at the cell surface of biologically active fusion and hemagglutinin/neuraminidase proteins of the paramyxovirus simian virus 5 from cloned cDNA. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[12]  G. Barber.  Vesicular stomatitis virus as an oncolytic vector. , 2004, Viral immunology.

[13]  L. Albritton,et al.  The Membrane-Proximal Domain of Vesicular Stomatitis Virus G Protein Functions as a Membrane Fusion Potentiator and Can Induce Hemifusion , 2002, Journal of Virology.

[14]  Atique U. Ahmed,et al.  Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. , 2002, Cancer research.

[15]  R. Zinkernagel,et al.  Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice , 1995, Journal of virology.

[16]  S. Woo,et al.  Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV , 2005, Hepatology.

[17]  K. Kristensson,et al.  SELECTIVE INFECTIONS OF OLFACTORY AND RESPIRATORY EPITHELIUM BY VESICULAR STOMATITIS AND SENDAI VIRUSES , 1987, Neuropathology and applied neurobiology.

[18]  S. Cramer,et al.  Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. , 2004, Virology.

[19]  R. Vile,et al.  Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. , 2000, Cancer research.

[20]  S. Harbaran,et al.  Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice , 2005, Cancer Gene Therapy.

[21]  R. Lamb,et al.  Fusion protein of the paramyxovirus SV5: destabilizing and stabilizing mutants of fusion activation. , 2000, Virology.

[22]  M. Steiner,et al.  Growth inhibition of prostate cancer by an adenovirus expressing a novel tumor suppressor gene, pHyde. , 2000, Cancer research.

[23]  L. Gong,et al.  Antitumor effect of antisense ODC adenovirus on human prostate cancer cells , 2005, Prostate Cancer and Prostatic Diseases.

[24]  M. Salman,et al.  Neutralizing Antibodies against Vesicular Stomatitis Viruses (Serotypes New Jersey and Indiana) in Horses in Costa Rica , 2002, Journal of Veterinary Diagnostic Investigation.

[25]  M. Whitt,et al.  Recombinant vesicular stomatitis viruses from DNA. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Z. Xiang,et al.  Recombinant vesicular stomatitis virus vectors as oncolytic agents in the treatment of high-grade gliomas in an organotypic brain tissue slice-glioma coculture model. , 2004, Journal of neurosurgery.

[27]  C. O'Shea.  Viruses: tools for tumor target discovery, and agents for oncolytic therapies – an introduction , 2005, Oncogene.

[28]  E. Genden,et al.  Fusogenic Vesicular Stomatitis Virus for the Treatment of Head and Neck Squamous Carcinomas , 2007, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[29]  A. García-Sastre,et al.  Syncytia Induction Enhances the Oncolytic Potential of Vesicular Stomatitis Virus in Virotherapy for Cancer , 2004 .